Search the Newsreel

Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more

Check out the companies making the biggest moves premarket: Replimune Group — Shares were up over 130% for the clinical-stage biotechnology company after a Food and Drug Administration advisory panel voted in favor of the company's RP1 drug trial results for a type of …

Replimune stock upgraded at Cantor on FDA vote (REPL:NASDAQ)

Replimune (REPL) shares rebounded following an upgrade by Cantor Fitzgerald. The upgrade came after an FDA advisory committee voted favorably for the company's lead drug, RP1, which targets melanoma. This positive development occurred despite a prior multi-day decline in the stock earlier in the …

REPL Stock Jumps As FDA Panel Backs Melanoma Drug

Replimune Group Inc. (REPL) stock jumped significantly after an FDA advisory panel voted 10-3 in favor of the efficacy data for its melanoma therapy, RP1 plus nivolumab, from the IGNYTE trial. This positive recommendation de-risks the company's ongoing Biologics License Application (BLA) resubmission ahead …

Proximus : Résultats financiers du Groupe Proximus – Deuxième trimestre 2026

Replimune stock surges on positive AdCom vote (REPL:NASDAQ)

Replimune's stock more than doubled in post-market trading after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted favorably on the company's lead asset, RP1. This positive AdCom vote precedes a key target date of August 2. The significant surge indicates strong investor …

Imunon (IMNN.US) will release its earnings report on August 4.

Imunon (IMNN.US) is scheduled to release its earnings report on August 4. This announcement provides investors with a key date to anticipate financial results from the company.

IMUNON reports faster-than-expected enrollment in ovarian cancer trial

IMUNON Inc. has announced that enrollment for its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer is progressing faster than anticipated, with an enrollment rate exceeding projections. The company expects to complete enrollment by the second quarter of 2029 and highlighted …

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

An FDA advisory panel voted 10-3 in favor of Replimune Group's experimental melanoma therapy, despite regulators' earlier concerns about the trial design and data. This recommendation follows a contentious meeting and a significant drop in Replimune's stock price after a critical FDA analysis. The …

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's meeting of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies …

Bragar Eagel & Squire, P.C. is Investigating Replimune

Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Replimune Group Inc. following a significant stock drop. The investigation comes after the FDA deemed Replimune's single-arm mid-stage study for its drug RP1 for skin cancer as "not interpretable," …

Maximus Data Breach Lawsuit Investigation

Shamis & Gentile P.A. is investigating a data breach at Maximus US Services Inc., a large government services company, which occurred around April 27, 2026. This breach exposed sensitive personal information, including names, dates of birth, and Social Security numbers, through the Nebraska Provider …

Maximus Data Breach Exposes Sensitive Personal Info Including SSNs

Maximus US Services Inc., a government services company, disclosed a data breach that exposed sensitive personal information due to a security incident involving the Nebraska Provider Data Management System (PDMS). The breach, discovered on April 27, 2026, compromised first and last names, dates of …

Replimune’s RP-1 for melanoma wins over FDA adcom

Replimune Group Inc.'s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma, refractory to PD-1 therapy, received a positive vote from the U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The committee voted 10-3 that the efficacy results from the Ignyte phase II study …

Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL)

Replimune Group, Inc. has been downgraded to 'Sell' due to ongoing FDA concerns regarding its RP1 + OPDIVO combination for advanced melanoma. The FDA's briefing documents highlight issues with the reliance on the single-arm IGNYTE trial, lack of a control arm, and a questionable …

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. is experiencing rapid and exceeding-expectations enrollment in its pivotal Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. This strong momentum is attributed to promising survival data from the Phase 2 OVATION 2 study and a favorable safety profile, with …

Replimune Faces FDA Panel on RP1 Melanoma Therapy

Replimune will present data for its RP1 plus nivolumab therapy for advanced melanoma to an FDA advisory panel. The company is seeking accelerated approval for RP1, citing positive outcomes from the IGNYTE trial and previous FDA feedback, arguing its efficacy and safety profile justify …

Replimune Seeks FDA Advisory Committee Backing for RP1 + nivolumab; IGNYTE ORR 33.6% & DOR 24.8 mos

Replimune

SLP|Simulations Plus Inc|Price:18.340|Chg%:+0.010

TradingKey provides a comprehensive stock analysis for Simulations Plus Inc (SLP), highlighting its healthy fundamentals, high growth potential, and current "Hold" rating from analysts with an average target price of $19.83. Despite a recent turnaround to a loss, the company's valuation is considered fairly …

Replimune Group (REPL) Projected to Announce Quarterly Earnings on Thursday

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

Imunon Inc. provided an update on its Phase 3 OVATION 3 trial for IMNN-001 in ovarian cancer, reporting significantly accelerated site activation and patient enrollment speeds that exceed industry benchmarks. The company anticipates full enrollment by Q2 2029 and has scheduled interim analyses that …

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC for $18.50 per share in cash. KSF is seeking to determine if this consideration and the process leading to it are adequate, …

Imunon Inc (IMNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Imunon Inc (IMNN), detailing its current stock price momentum, support and resistance levels, and various technical indicator readings. It highlights that IMNN's price momentum score is 5.09, suggesting range-bound swing trading as the stock trades between $1.28 …

Replimune Group Number of Employees 2026 | Employee Count & Headcount Data

Replimune Group, a Pharmaceuticals company founded in 2015 and headquartered in Woburn, Massachusetts, had approximately 469 employees worldwide as of March 2026, representing a 35.9% growth from 2023 but a 1.2% decline year-over-year. The company's workforce is concentrated in the United States, followed by …

Imunon Inc (IMNN) Institutional Confidence

This article from TradingKey provides an overview of Imunon Inc.'s (IMNN) institutional confidence score. It highlights the company's current stock price, market cap, and details key institutional shareholdings and their recent activity. The institutional confidence score remains at 3.00 with no change from the …

MAXIMUS Number of Employees 2026 | Employee Count & Headcount Data

MAXIMUS, Inc. (MMS) had approximately 36,490 employees worldwide as of March 2026, representing a 6.6% decline since 2023. Despite this reduction in headcount, the company is actively hiring, with 2,364 active job postings in 2026. The article details the company's workforce distribution by country, …

REPL: Replimune Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides a current overview of Replimune Group Inc. (REPL) stock, including its latest price, market performance, and financial fundamentals. It highlights recent news regarding a significant stock drop due to FDA documents and ongoing securities fraud investigations, alongside details on upcoming earnings …

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company and/or members of its senior management may have violated …

Replimune Group, Inc. SEC Filing (Jul 28, 2026)

This article announces an SEC filing (type ARS) by Replimune Group, Inc. (REPL) on July 28, 2026. The filing was accepted by the SEC on July 28, 2026, at 06:26 PM and is available as a PDF document. StockTitan provides additional context, including filing …

Replimune tanks on FDA concerns about its skin cancer therapy

Replimune Group Inc. (NASDAQ: REPL) saw its stock slide by over 37% after the FDA released documents raising serious questions about its skin cancer treatment, RP1, ahead of an advisory committee meeting. The FDA deemed the data package "not interpretable" due to the single-arm …

Optimum's Q2 results discussion will have no dial-in Aug. 6

Previsioni su azioni Azimut Holding, Eni, Italgas

Imunon Inc (IMNN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Imunon Inc (IMNN), noting its current valuation score of 6.86, which ranks 274 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio, and states that P/B, P/S, and P/CF relevant …

Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock.

The biotech is seeking approval for its first commercial product in combination with Bristol Myers Squibb’s Opdivo. Continue Reading

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz has initiated a securities fraud investigation into Replimune Group Inc. (REPL) after the FDA deemed the company's mid-stage study for its skin cancer drug RP1 "not interpretable." This FDA assessment caused Replimune's stock price to fall by …

FDA staff reiterate concerns about Replimune skin cancer treatment

The FDA has again expressed concerns regarding Replimune's investigational skin cancer treatment, RP1, ahead of an advisory committee meeting. Regulators cite insufficient data to support approval, specifically questioning the reliance on a single-arm trial that combines RP1 with Opdivo in patients who have failed …

Investigation launched into Replimune after FDA doubts RP1 therapy data, shares drop 30%.

Johnson Fistel, PLLP has launched an investigation into Replimune Group, Inc. following a 30% drop in its share price. This decline occurred after the FDA released briefing documents that questioned the efficacy data for Replimune's RP1 therapy when combined with nivolumab, citing insufficient evidence …